Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312528 | 0.91 | CYP2D6 (0.47) | LTA4HHRH3SCN5ASCN9AFAAH | |
| SCHEMBL5313809 | 0.89 | LTA4H (0.67) | LTA4HFAAHMCHR2MCHR1 | |
| SCHEMBL5312878 | 0.89 | LTA4H (0.59) | LTA4HHRH3SCN5ASCN9AFAAH | |
| SCHEMBL5310186 | 0.81 | LTA4H (0.69) | LTA4HFAAHMCHR2MCHR1 | |
| SCHEMBL3043169 | 0.81 | LTA4H (0.77) | LTA4HHRH3FAAH | |
| SCHEMBL5317798 | 0.81 | LTA4H (0.77) | LTA4HHRH3FAAH | |
| SCHEMBL5313875 | 0.80 | MEN1 (0.54) | LTA4HHRH3SCN5ASCN9AFAAH | |
| SCHEMBL5660153 | 0.80 | LTA4H (0.54) | LTA4HFAAHMCHR2MCHR1 | |
| SCHEMBL5663496 | 0.79 | LTA4H (0.60) | LTA4HHRH3FAAHMCHR2MCHR1 | |
| SCHEMBL5661080 | 0.76 | LTA4H (0.59) | LTA4HHRH3FAAHMCHR2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885HRH3 15/4885SCN5A 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.